Established in 2013 by Michael and Ann Hankin and the Partners of Brown Advisory, Inc.

MICHAEL and ANN HANKIN met at Emory University and went on to share the same educational background, graduating from Emory in 1979 with both a BA and an MA along with Phi Beta Kappa and summa cum laude honors. They also graduated together from the University of Virginia School of Law with JDs in 1982.

Mike is president and chief executive officer of Brown Advisory, a position he has held since the firm became independent from Bankers Trust/Alex. Brown & Sons in 1998. Brown Advisory is a leading independent investment firm that offers a wide range of solutions to institutions, corporations, nonprofits, families, and individuals. The firm’s mission is to make a material and positive difference in the lives of clients by providing them first-rate investment performance, customized strategic advice, and the highest level of personalized service. Today, Brown Advisory has 340 employees and oversees more than $42 billion in assets for clients in all 50 states and 20 countries around the world.

Mike’s contributions to the community include serving as trustee and vice-chairman of Johns Hopkins Medicine and trustee of The Johns Hopkins University, the Johns Hopkins University Applied Physics Lab, and the Baltimore Community Foundation. In addition, his deep concern about the environment has been expressed through his roles as president of the Land Preservation Trust, trustee of the Center for Large Landscape Conservation, and chairman of the Waterfront Partnership of Baltimore, Inc., the lead organization in the effort to make Baltimore’s harbor “swimmable and fishable” by the year 2020.

Ann worked as an attorney at Piper & Marbury from 1982 to 1990 and then at U.S.F.& G. until 1992. Since then, Ann has been a devoted mother to her three children and dedicated partner to Mike while playing important leadership roles in the community. She was a leading force at The Bryn Mawr School, serving as chair of the largest capital campaign for a girls’ school in Baltimore, and then chair of the board for three years. Initially she declined serving as chair because she believed the role should be filled by an alumna, an issue that disappeared when the school then gave her an honorary degree. She has also served as a trustee of the Baltimore School for the Arts and Paul’s Place.

Apart from her family, Ann’s true love is music; she has sung as part of a choral group since her first year in college and today is an active member of the Canticle Singers, a women’s chorale.


SE-JIN LEE, the inaugural Michael and Ann Hankin and Partners of Brown Advisory Professor of Scientific Innovation, was born in Seoul in 1958, and came to the United States when he was five years old. He graduated summa cum laude from Harvard College in 1981. He then entered the Medical Scientist Training Program at the Johns Hopkins University School of Medicine, where he pursued his graduate studies with Daniel Nathans. After earning his MD/PhD in 1989, Lee joined the Carnegie Institution of Washington’s Department of Embryology, where, as a staff associate, he began investigating the role of secreted proteins in regulating embryonic development and adult tissue homeostasis. He returned to the Department of Molecular Biology and Genetics at Johns Hopkins as a faculty member in 1991.

At Johns Hopkins, Lee discovered the hormone myostatin. Muscle cells make myostatin, which circulates through the body and blocks muscle growth. Lee showed in laboratory mice that removal of the myostatin gene results in “mighty mice” that have twice the muscle mass of ordinary mice. By exploring the components in the cell that regulate myostatin, Lee has identified several potential therapeutic targets for diseases like muscular dystrophy and muscle wasting in AIDS patients and the elderly. Pharmaceutical companies are conducting multiple clinical trials for these diseases based upon Lee’s findings.

He continues to study how problems with myostatin communication contribute to disease progression, and he is working on manipulating proteins that interact with myostatin as a basis for new treatments for certain muscle diseases. Lee is a member of the National Academy of Sciences and a fellow at the American Association for the Advancement of Science.